FDA
-
-
-
-
-
-
-
FDA accepts GSK's bepirovirsen for priority review in hepatitis B treatment
-
-
-
-
-
-
-
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
-
-
-
-
-
-
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
-
-
-
-
-
-
-
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
-
-
-
-
-
-
-
Ionis reports olezarsen cut triglyceride levels up to 72% in pivotal trials
-
-
-
-
-
-
-
Ionis hosts innovation day, targets sustained cash flow by 2028
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

